Category Archives: Ulcerative Colitis

Nov. 6, 2020 12:00 UTC SER-301 is designed to target the physiological triggers of inflammation believed to be central to the underlying pathology of ulcerative colitis Program represents Seres second active clinical program targeting ulcerative colitis, in addition to its ongoing SER-287 Phase 2b study CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. Continue reading →

Ulcerative Colitis Treatment Market Overview The Global Ulcerative Colitis Treatment Market is showing positive signs of growth. With the current COVID-19 pandemic scenario, new business opportunities are sprouting in the market. Continue reading →

The globalUlcerative Colitisresearch report presents obligatory facts and statistics on trends & developments. Continue reading →

November 05, 2020 08:30 ET | Source: Enlivex Therapeutics Ltd Nes-Ziona, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd Continue reading →

Market Overview: Global Ulcerative Colitis Treatment market is anticipated to grow at a robust rate during the forecast period on account of the rising geriatric population across the world and the rising number of individuals diagnosed with chronic diseases such as cardiac disorders, diabetes, and various respiratory disorders. Growth in the region is attributed to various other factors, such as increasing awareness among the population regarding their health and ever-advancing technologies that are changing the face of hospitals and medical devices. Continue reading →

An innovative research study has been offered by Futuristic Reports, offering a comprehensive analysis of the Global Ulcerative Colitis Treatment Market where users can get an advantage from the comprehensive market research report with all the essential useful information. Continue reading →

EXTON, Pa., Nov. 9, 2020 /PRNewswire/ --According to the latest report published as part of Spherix'sRealWorld Dynamix: Biologic/Small Molecule Switching in IBD (EU)service, EU gastroenterologists (n=299) are adjusting their inflammatory bowel disease (IBD) treatment algorithms by increasing their biosimilar prescribing as well as their receptivity to new subcutaneous biologics. The Spherix study summarizes the wealth of patient-level data captured from 1,275 unique IBD patient records from France, Germany, Italy, Spain, and the United Kingdom (EU5) who were recently switched from one advanced therapy to another Continue reading →

CMR has added the addition of the Global Ulcerative Colitis Immunology Drugs Market The report focuses on global major leading players with information such as company profiles, product picture and specification. Scope of the Report: This report focuses on the Ulcerative Colitis Immunology Drugs market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa Continue reading →

Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed to terminate their previously signed collaboration and licence agreement to develop BBT-877. In July 2019, Boehringer entered a deal with Bridge Biotherapeuticsto develop the drug candidate, BBT-877, for the treatment of fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Continue reading →

Boehringer Ingelheim and South Koreas Bridge Therapeutics have decided to axe their collaboration over a potential new drug for idiopathic pulmonary fibrosis (IPF), BBT-877. Continue reading →